Skip to main content
Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: Time to response for clinical and patient-reported outcomes in patients with psoriatic arthritis treated with tofacitinib, adalimumab, or placebo

Fig. 4

Time to initial PASDAS response: a OPAL Broaden, b OPAL Beyond (FAS). Response defined for PASDAS as post-baseline score of ≤ 3.2 and > 1.6-point improvement from baseline (analyzed for patients with baseline PASDAS > 3.2). BID, twice daily; FAS, full analysis set; PASDAS, Psoriatic Arthritis Disease Activity Score; Q2W, once every 2 weeks; SC, subcutaneous

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us